CL2022003796A1 - Receptores antigénicos quiméricos con especificidad para bcma y usos de estos - Google Patents
Receptores antigénicos quiméricos con especificidad para bcma y usos de estosInfo
- Publication number
- CL2022003796A1 CL2022003796A1 CL2022003796A CL2022003796A CL2022003796A1 CL 2022003796 A1 CL2022003796 A1 CL 2022003796A1 CL 2022003796 A CL2022003796 A CL 2022003796A CL 2022003796 A CL2022003796 A CL 2022003796A CL 2022003796 A1 CL2022003796 A1 CL 2022003796A1
- Authority
- CL
- Chile
- Prior art keywords
- bcma
- chimeric antigen
- antigen receptors
- cells
- specificity
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 5
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 title 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 abstract 6
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 210000004180 plasmocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/13—Antibody-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
El antígeno de maduración de células B (BCMA)se expresa en células plasmáticas malignas. La presente invención proporciona receptores antigénicos quiméricos específicos de BCMA y células que expresan tales receptores antigénicos quiméricos. En determinadas modalidades, las células modificadas genéticamente que expresan los receptores antigénicos quiméricos de la presente invención son capaces de inhibir el crecimiento de tumores que expresan BCMA. Las células modificadas genéticamente de la invención son útiles para el tratamiento de enfermedades y trastornos en los que es conveniente y/o terapéuticamente beneficioso una respuesta inmunitaria inducida o regulada positivamente dirigida a BCMA. Por ejemplo, las células modificadas genéticamente que expresan los receptores antigénicos quiméricos específicos de BCMA de la invención son útiles para el tratamiento de varios cánceres, que incluye el mieloma múltiple.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862700615P | 2018-07-19 | 2018-07-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022003796A1 true CL2022003796A1 (es) | 2023-07-07 |
Family
ID=67515170
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000142A CL2021000142A1 (es) | 2018-07-19 | 2021-01-18 | Receptores antigénicos quiméricos con especificidad para bcma y usos de estos. |
CL2022003796A CL2022003796A1 (es) | 2018-07-19 | 2022-12-28 | Receptores antigénicos quiméricos con especificidad para bcma y usos de estos |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021000142A CL2021000142A1 (es) | 2018-07-19 | 2021-01-18 | Receptores antigénicos quiméricos con especificidad para bcma y usos de estos. |
Country Status (26)
Country | Link |
---|---|
US (1) | US20200023010A1 (es) |
EP (2) | EP3823665B1 (es) |
JP (2) | JP7404335B2 (es) |
KR (1) | KR20210035832A (es) |
CN (1) | CN112437671A (es) |
AU (1) | AU2019308290A1 (es) |
BR (1) | BR112021000919A2 (es) |
CA (1) | CA3106612A1 (es) |
CL (2) | CL2021000142A1 (es) |
CO (1) | CO2021000334A2 (es) |
DK (1) | DK3823665T3 (es) |
EA (1) | EA202190315A1 (es) |
ES (1) | ES2973946T3 (es) |
FI (1) | FI3823665T3 (es) |
IL (1) | IL279979A (es) |
LT (1) | LT3823665T (es) |
MA (1) | MA65527B1 (es) |
MD (1) | MD3823665T2 (es) |
MX (1) | MX2021000532A (es) |
PH (1) | PH12021550036A1 (es) |
PL (1) | PL3823665T3 (es) |
PT (1) | PT3823665T (es) |
RS (1) | RS65384B1 (es) |
SG (1) | SG11202100221VA (es) |
SI (1) | SI3823665T1 (es) |
WO (1) | WO2020018825A1 (es) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113164519A (zh) | 2018-08-01 | 2021-07-23 | 南克维斯特公司 | 用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统 |
JP2022535005A (ja) | 2019-05-30 | 2022-08-04 | レンティジェン・テクノロジー・インコーポレイテッド | 抗bcma免疫療法によりがんを処置するための組成物および方法 |
US11919965B2 (en) * | 2019-12-06 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies |
US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
US20230346937A1 (en) * | 2020-02-13 | 2023-11-02 | Beijing Immunochina Pharmaceuticals Co., Ltd. | Optimization of chimeric antigen receptor |
EP4136111A1 (en) * | 2020-04-14 | 2023-02-22 | Julius-Maximilians-Universität Würzburg | Combination therapy of atra or other retinoids with immunotherapeutic agents binding to bcma |
CN112812186B (zh) * | 2021-02-08 | 2022-07-29 | 华道(上海)生物医药有限公司 | 一种抗b细胞成熟抗原的纳米抗体及其应用 |
CN113109572A (zh) * | 2021-04-01 | 2021-07-13 | 苏州才博医学科技有限公司 | 一种检测自体cart细胞体液性免疫原性的方法 |
CN117730091A (zh) * | 2021-04-13 | 2024-03-19 | 悟境股份有限公司 | 改善的嵌合抗原受体及其用途 |
WO2023284875A1 (zh) * | 2021-07-16 | 2023-01-19 | 克莱格医学有限公司 | 嵌合抗原受体 |
CN115466331B (zh) * | 2021-11-18 | 2023-05-30 | 合源生物科技(天津)有限公司 | 靶向bcma的嵌合抗原受体及其应用 |
WO2023098846A1 (zh) * | 2021-12-03 | 2023-06-08 | 江苏先声药业有限公司 | 抗bcma纳米抗体及其应用 |
CN113980907B (zh) * | 2021-12-24 | 2022-03-15 | 山东兴瑞生物科技有限公司 | 一种抗flt3嵌合抗原受体修饰的t细胞及其在制备治疗aml药物中的应用 |
WO2023152747A1 (en) * | 2022-02-09 | 2023-08-17 | Hadasit Medical Research Services And Development Ltd. | Anti-bcma car to target immune-related disorders, compositions and method thereof |
WO2023193662A1 (zh) * | 2022-04-03 | 2023-10-12 | 上海先博生物科技有限公司 | 靶向bcma的嵌合抗原受体及其应用 |
CN117143248A (zh) * | 2022-05-24 | 2023-12-01 | 合源康华医药科技(北京)有限公司 | 靶向bcma-cd19的双特异性嵌合抗原受体及其应用 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
EP0228458B2 (en) | 1985-07-05 | 1997-10-22 | Whitehead Institute For Biomedical Research | Epithelial cells expressing foreign genetic material |
US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
EP0378576B1 (en) | 1987-09-11 | 1995-01-18 | Whitehead Institute For Biomedical Research | Transduced fibroblasts and uses therefor |
JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
EP0732397A3 (en) | 1988-02-05 | 1996-10-23 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
EP0556345B2 (en) | 1990-10-31 | 2005-10-12 | Cell Genesys, Inc. | Retroviral vectors useful for gene therapy |
US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
AU2001243288B2 (en) | 2000-02-24 | 2005-11-24 | Life Technologies Corporation | Simultaneous stimulation and concentration of cells |
US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
TR201820015T4 (tr) | 2010-12-09 | 2019-01-21 | Univ Pennsylvania | Kanser Tedavisi İçin Kimerik Antijen Reseptörü-Modifiye Edilmiş T Hücrelerinin Kullanılması |
NZ743310A (en) | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
EP3276000A3 (en) | 2012-05-25 | 2018-02-21 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
RU2747457C2 (ru) * | 2014-07-24 | 2021-05-05 | Блубёрд Био, Инк. | Химерные антигенные рецепторы к bcma |
PE20171653A1 (es) | 2015-04-13 | 2017-11-13 | Pfizer | Receptores del antigeno quimerico dirigidos al antigeno de maduracion de celulas b |
EP3674328B1 (en) * | 2018-02-01 | 2023-12-13 | Nanjing Iaso Biotechnology Co., Ltd. | Chimeric antigen receptor (car) binding to bcma, and uses thereof |
-
2019
- 2019-07-18 MX MX2021000532A patent/MX2021000532A/es unknown
- 2019-07-18 MD MDE20210484T patent/MD3823665T2/ro unknown
- 2019-07-18 SI SI201930706T patent/SI3823665T1/sl unknown
- 2019-07-18 EA EA202190315A patent/EA202190315A1/ru unknown
- 2019-07-18 WO PCT/US2019/042452 patent/WO2020018825A1/en active Application Filing
- 2019-07-18 EP EP19749097.2A patent/EP3823665B1/en active Active
- 2019-07-18 LT LTEPPCT/US2019/042452T patent/LT3823665T/lt unknown
- 2019-07-18 KR KR1020217004579A patent/KR20210035832A/ko unknown
- 2019-07-18 PT PT197490972T patent/PT3823665T/pt unknown
- 2019-07-18 EP EP23215003.7A patent/EP4324851A3/en active Pending
- 2019-07-18 RS RS20240417A patent/RS65384B1/sr unknown
- 2019-07-18 SG SG11202100221VA patent/SG11202100221VA/en unknown
- 2019-07-18 CN CN201980048197.7A patent/CN112437671A/zh active Pending
- 2019-07-18 JP JP2021502826A patent/JP7404335B2/ja active Active
- 2019-07-18 AU AU2019308290A patent/AU2019308290A1/en active Pending
- 2019-07-18 ES ES19749097T patent/ES2973946T3/es active Active
- 2019-07-18 CA CA3106612A patent/CA3106612A1/en active Pending
- 2019-07-18 BR BR112021000919-1A patent/BR112021000919A2/pt unknown
- 2019-07-18 DK DK19749097.2T patent/DK3823665T3/da active
- 2019-07-18 MA MA65527A patent/MA65527B1/fr unknown
- 2019-07-18 FI FIEP19749097.2T patent/FI3823665T3/fi active
- 2019-07-18 US US16/516,060 patent/US20200023010A1/en active Pending
- 2019-07-18 PL PL19749097.2T patent/PL3823665T3/pl unknown
-
2021
- 2021-01-06 IL IL279979A patent/IL279979A/en unknown
- 2021-01-07 PH PH12021550036A patent/PH12021550036A1/en unknown
- 2021-01-15 CO CONC2021/0000334A patent/CO2021000334A2/es unknown
- 2021-01-18 CL CL2021000142A patent/CL2021000142A1/es unknown
-
2022
- 2022-12-28 CL CL2022003796A patent/CL2022003796A1/es unknown
-
2023
- 2023-12-12 JP JP2023208956A patent/JP2024028944A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CL2021000142A1 (es) | 2021-07-02 |
AU2019308290A1 (en) | 2021-02-18 |
PL3823665T3 (pl) | 2024-06-03 |
PT3823665T (pt) | 2024-02-26 |
EA202190315A1 (ru) | 2021-04-16 |
WO2020018825A1 (en) | 2020-01-23 |
KR20210035832A (ko) | 2021-04-01 |
MD3823665T2 (ro) | 2024-05-31 |
BR112021000919A2 (pt) | 2021-04-27 |
JP7404335B2 (ja) | 2023-12-25 |
US20200023010A1 (en) | 2020-01-23 |
EP4324851A3 (en) | 2024-05-15 |
SI3823665T1 (sl) | 2024-03-29 |
ES2973946T3 (es) | 2024-06-25 |
LT3823665T (lt) | 2024-02-26 |
MA65527B1 (fr) | 2024-05-31 |
RS65384B1 (sr) | 2024-04-30 |
JP2024028944A (ja) | 2024-03-05 |
SG11202100221VA (en) | 2021-02-25 |
IL279979A (en) | 2021-03-01 |
CO2021000334A2 (es) | 2021-01-29 |
EP3823665A1 (en) | 2021-05-26 |
DK3823665T3 (da) | 2024-03-04 |
CN112437671A (zh) | 2021-03-02 |
CA3106612A1 (en) | 2020-01-23 |
EP3823665B1 (en) | 2024-01-24 |
FI3823665T3 (fi) | 2024-03-01 |
JP2021531004A (ja) | 2021-11-18 |
PH12021550036A1 (en) | 2021-09-20 |
MX2021000532A (es) | 2021-04-12 |
EP4324851A2 (en) | 2024-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022003796A1 (es) | Receptores antigénicos quiméricos con especificidad para bcma y usos de estos | |
CL2021000131A1 (es) | Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos. | |
CL2020003028A1 (es) | Anticuerpos anti-cd33, anticuerpos bispecíficos anti-cd33/anti-cd3 y sus usos. | |
DOP2018000212A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
CO2019007868A2 (es) | Anticuerpos agonistas anti-icos y sus usos | |
CL2021001573A1 (es) | Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos. | |
CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
CL2018003153A1 (es) | Moléculas de anticuerpo para el tratamiento del cáncer. | |
CO2017000510A2 (es) | Constructos de car | |
AR110676A1 (es) | Tratamiento del cáncer utilizando receptores de antígenos quiméricos | |
CL2020003285A1 (es) | Anticuerpos anti-psma x anti-cd28 biespecificos y usos de estos. | |
EA201992131A1 (ru) | Высокоаффинные специфичные к mage-a1 tcr и их применение | |
MX2020004741A (es) | Nuevos receptores de las celulas t modificados geneticamente y terapias immunologicas que emplean los mismos. | |
ECSP18011248A (es) | Diacuerpos monovalentes biespecíficos que son capaces de unirse a b7-h3 y cd3, y usos de los mismos | |
CL2017003007A1 (es) | Anticuerpos anti-cd40 y sus usos | |
CU24437B1 (es) | Anticuerpos agonistas de anti-gitr y composiciones de los mismos | |
CL2017001660A1 (es) | Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de motivo inhibidor de inmunorreceptor basado en tirosina (tigit) | |
CO2020014345A2 (es) | Anticuerpos específicos para gucy2c y sus usos | |
AR111288A1 (es) | Anticuerpos anti-phf-tau y sus usos | |
CL2022000130A1 (es) | Receptores de antígenos quiméricos con especificidad mage-a4 y usos de los mismos. | |
CL2017000806A1 (es) | Compuestos anti-tnf | |
UY36289A (es) | ANTICUERPOS MONOCLONALES QUE ENLAZAN INMUNOESPECIFICAMENTE A CD123 y COMPOSICIONES QUE LOS CONTIENEN | |
CO2019013654A2 (es) | Receptores de antígenos quiméricos que se dirigen a flt3 | |
EA201791554A1 (ru) | Биспецифичные антитела против cd3 и cd20 |